全文获取类型
收费全文 | 467篇 |
免费 | 91篇 |
出版年
2024年 | 2篇 |
2023年 | 10篇 |
2022年 | 14篇 |
2021年 | 33篇 |
2020年 | 19篇 |
2019年 | 31篇 |
2018年 | 22篇 |
2017年 | 23篇 |
2016年 | 23篇 |
2015年 | 28篇 |
2014年 | 56篇 |
2013年 | 31篇 |
2012年 | 17篇 |
2011年 | 26篇 |
2010年 | 22篇 |
2009年 | 24篇 |
2008年 | 20篇 |
2007年 | 26篇 |
2006年 | 19篇 |
2005年 | 19篇 |
2004年 | 15篇 |
2003年 | 9篇 |
2002年 | 6篇 |
2001年 | 2篇 |
2000年 | 3篇 |
1999年 | 4篇 |
1998年 | 2篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 6篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1988年 | 2篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1976年 | 4篇 |
1975年 | 5篇 |
1974年 | 3篇 |
1973年 | 4篇 |
排序方式: 共有558条查询结果,搜索用时 15 毫秒
21.
Saleh Al-Quraishy Mostafa A. Abdel-Maksoud Esam M. Al-Shaebi Mohamed A. Dkhil 《Saudi Journal of Biological Sciences》2021,28(2):1374-1379
Malaria is a lethal parasitic disease affecting over two hundred million people worldwide and kills almost half a million people per year. Until now, there is no curative treatment for this disease that has a substantial morbidity. The available chemotherapeutic agents are unable to completely control the infection with the continuous appearance of drug resistance. Consequently, the search for new therapeutic agents with high safety profiles and low side effects is of paramount importance. Several natural products have been investigated and proven to have antimalarial effects either in vivo or in vitro. A large number of plants have been studied globally for their antimalarial activities. However, studies that have been conducted in this field in Saudi Arabia are not enough. This article presents global and local research on the need for novel natural antimalarial agents with a particular emphasis on studies involving plants from Saudi Arabian flora. 相似文献
22.
Locally advanced rectal cancer requires a multidisciplinary management, traditionally based on neo-adjuvant (chemo) radiotherapy, conservative surgery with total mesorectal excision and adjuvant chemotherapy. Despite effective in term of local control, this strategy is linked to a high risk of distant metastasis (up to 30%). In this context, recent published randomized phase III clinical trials have tested the potential benefits with a different sequencing and/or intensification of the standard components of the trimodal therapy.Here, we briefly assess the efficacy and discuss the clinical relevance of total neoadjuvant treatment with a focus on indications and results in the short-course radiotherapy followed by chemotherapy use for this setting of patients. Long term results and additional prospective studies are necessary to more accurately estimate the clinical benefit and further establish the role of total neoadjuvant therapy in locally advanced rectal cancer disease. 相似文献
23.
Maria Davern Noel E. Donlon Andrew Sheppard Fiona O’ Connell Conall Hayes Anshul Bhardwaj Emma Foley Dermot O’ Toole Niamh Lynam-Lennon Narayanasamy Ravi John V. Reynolds Stephen G. Maher Joanne Lysaght 《Translational oncology》2021,14(6):101062
Use of immune checkpoint inhibitors (ICIs) with chemotherapy to enhance responses in oesophageal adenocarcinoma (OAC) is an attractive approach. We identified subpopulations of OAC cells expressing inhibitory immune checkpoint (IC) ligands (PD-L1, PD-L2 and CD160) and receptors (PD-1, TIGIT, TIM-3, LAG-3 and A2aR) in vitro and in ex vivo biopsies. Combination chemotherapy regimens FLOT and CROSS promote a more immune-resistant phenotype through upregulation of IC ligands and receptors on OAC cells in vitro. Importantly, this study investigated if OAC cells, enriched for ICs exhibited a more stem-like and senescent-like phentoype. FLOT preferentially upregulates PD-L1 on a stem-like OAC cell phenotype, defined by ALDH activity. Expression of senescence-associated β-galactosidase is induced in a subpopulation of OAC cells following FLOT and CROSS chemotherapy treatment, along with enhanced expression of TIM-3 and A2aR ICs. Blockade of PD-1 signalling in OAC cells induced apoptosis and enhanced FLOT and CROSS chemotherapy toxicity in vitro. Upregulation of ICs on OAC cells following chemotherapy may represent potential mechanisms of chemo-immune resistance. Combination ICIs may be required to enhance the efficacy of chemotherapy and immunotherapy in OAC patients. 相似文献
24.
Abdulaziz A. Alsaif Tarique N. Hasan Gowhar Shafi Naveed A. Syed Mohammed A. Alsaif Abdullah H. Al-Assaf Ali A. Alshatwi 《Cancer epidemiology》2013,37(5):762-766
Chemotherapy has been used widely to treat cancer, both as a systemic therapy and as a local treatment. Unfortunately, many types of cancer are still refractory to chemotherapy. The mechanisms of anticancer drug resistance have been extensively explored but have not been fully characterized. This study analyzed the occurrences of polymorphism (SNP) in the MDR1 gene in breast cancer patients and determined a possible association with chemotherapy. The study group included one hundred breast carcinoma patients who subsequently received chemotherapy (the regimen generally consisted of commonly used drugs such as cyclophosphamide, adriamycin, 5-fluorouracil, docetaxel and their combinations). Blood samples from 100 healthy individuals are used, as controls were also genotyped for the MDR1 gene. This investigation revealed a significant correlation with response to various regimens of chemotherapy showing a low response to therapy with the CT/TT genotype at (exon 12) 1236 codon (p < 0.001). These findings demonstrate, for the first time, that the polymorphisms in (exon 12) 1236 codon of the MDR1 gene greatly influence the drug response in patients from the Arab population of Saudi Arabia. 相似文献
25.
Elisa Tran Annabelle Chow Takeshi Goda Amy Wong Kim Blakely Michelle Rocha Samira Taeb Van C. Hoang Stanley K. Liu Urban Emmenegger 《Biochemical and biophysical research communications》2013
ATG4B belongs to the autophagin family of cysteine proteases required for autophagy, an emerging target of cancer therapy. Developing pharmacological ATG4B inhibitors is a very active area of research. However, detailed studies on the role of ATG4B during anticancer therapy are lacking. By analyzing PC-3 and C4-2 prostate cancer cells overexpressing dominant negative ATG4BC74Ain vitro and in vivo, we show that the effects of ATG4BC74A are cell type, treatment, and context-dependent. ATG4BC74A expression can either amplify the effects of cytotoxic therapies or contribute to treatment resistance. Thus, the successful clinical application of ATG4B inhibitors will depend on finding predictive markers of response. 相似文献
26.
目的:比较化疗敏感性不同弥漫性大B细胞淋巴瘤的蛋白质表达差异,寻找可反映大B细胞淋巴瘤化疗敏感性的标志物。方法:通过肿瘤药物敏感试验选取化疗高敏感性和低敏感性大B细胞淋巴瘤组织,进行蛋白质组学比较研究后得出差异表达蛋白;对在高敏感组中高表达的埃兹蛋白(Ezrin)进一步行免疫印迹验证,应用免疫组化技术检测在临床病例中的表达情况。结果:建立了化疗高敏感和低敏感大B细胞淋巴瘤差异表达蛋白质凝胶2D图谱,鉴定了28种差异表达蛋白,发现Ezrin蛋白在化疗高敏感组表达高于低敏感组,免疫印迹和免疫组化结果也进一步证实了Ezrin的这一表达状态。结论:Ezrin蛋白表达在化疗敏感性不同大B细胞淋巴瘤中存在差别,可能作为预测淋巴瘤化疗敏感性的候选标志物。 相似文献
27.
Beno?te Méry Jean-Baptiste Guy Sophie Espenel Anne-Sophie Wozny Stéphanie Simonet Alexis Vallard Gersende Alphonse Dominique Ardail Claire Rodriguez-Lafrasse Nicolas Magné 《World journal of stem cells》2016,8(1):13-21
Head and neck squamous cell cancer(HNSCC) is the sixth most common cancer in the world. Effective therapeutic modalities such as surgery, radiation, chemotherapy and combinations of each are used in the management of the disease. In most cases, treatment fails to obtain total cancer cure. In recent years, it appears that one of the key determinants of treatment failure may be the presence of cancer stem cells(CSCs) that escape currently available therapies. CSCs form a small portion of the total tumor burden but may play a disproportionately important role in determining outcomes. CSCs have stem features such as self-renewal, high migration capacity, drug resistance, high proliferation abilities. A large body of evidence points to the fact that CSCs are particularly resistant to radiotherapy and chemotherapy. In HNSCC, CSCs have been increasingly shown to have an integral role in tumor initiation, disease progression, metastasis and treatment resistance. In the light of such observations, the present review summarizes biological characteristics of CSCs in HNSCC, outlines targeted strategies for the successful eradication of CSCs in HNSCC including targeting the self-renewal controlling pathways, blocking epithelial mesenchymal transition, niche targeting, immunotherapy approaches and highlights the need to better understand CSCs biology for new treatments modalities. 相似文献
28.
29.
30.
目的:研究洛铂与顺铂联合吉西他滨用于晚期肺癌患者化疗的临床疗效,为临床治疗提供依据。方法:选取2013年1月到2015年1月我院收治的晚期肺癌患者190例,按照随机数字表法将患者分为I组和II组,每组95例,I组给予洛铂联合吉西他滨治疗,II组给予顺铂联合吉西他滨治疗,应用欧洲癌症研究和治疗组织(EORTC)的生命质量测定量表(QLQ-C30)评价治疗前、后患者的生活质量,比较两组近期疗效、远期疗效以及不良反应。结果:两组近期疗效比较无统计学意义(P0.05);I组平均缓解期(6.33±1.82)月显著长于II组的(5.13±0.84)月,I组中位生存期为(9.95±2.31)月显著长于II组的(7.82±1.24)月,比较差异均有统计学意义(P0.05);治疗后两组QLQ-C30评分均显著提高,且I组高于II组,比较差异具有统计学意义(P0.05);I组骨髓抑制发生率显著高于II组,恶心、呕吐发生率显著低于II组,比较差异具有统计学意义(P0.05)。结论:洛铂与顺铂联合吉西他滨用于晚期肺癌患者化疗近期疗效相当,洛铂联合吉西他滨具有较好远期疗效,且能提高患者生活质量,但骨髓抑制发生率较高。 相似文献